Evidence map›Paper›PMID 35502681›Full record

ArticleEuropean journal of heart failure2022

Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality.

Benedikt Schrage, Lars H Lund, Lina Benson, Ulf Dahlström, Ramin Shadman, Cecilia Linde, Frieder Braunschweig, Wayne C Levy, Gianluigi Savarese

Open access · hybridAbstract read
In one paragraph

Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. 2024 update in heart failure.ESC heart failure · 2025
    Review
  8. Article
  9. Article
  10. Regional disparity on patient characteristics and perceptions after implantable cardioverter-defibrillator implantation: results from an EHRA patient survey.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Benedikt SchrageDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-9041-3922
Lars H LundDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Lina BensonDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Ulf DahlströmDepartment of Cardiology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Ramin ShadmanSouthern California Permanente Medical Group, Los Angeles, CA, USA.
Cecilia LindeDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Frieder BraunschweigDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Wayne C LevyUniversity of Washington, UW Heart Institute, Seattle, WA, USA.
Gianluigi SavareseDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7732-0887
Karolinska University Hospital · SEKarolinska Institutet · SELinköping University · SELos Angeles Medical Center · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsUse of implantable cardioverter-defibrillators (ICD) for primary prevention of sudden cardiac death (SCD) in heart failure with reduced ejection fraction (HFrEF) is limited. We aimed to investigate barriers to ICD use in HFrEF while considering the predicted risk of mortality and SCD. METHOD AND

resultsPatients from the SwedeHF registered in 2011-2018 and with an indication for primary prevention ICD were analysed. The Seattle Proportional Risk and Seattle Heart Failure Models were used to predict the proportional SCD and all-cause mortality risk, respectively. A multivariable logistic regression model was fitted to identify independent predictors of ICD use/non-use; Cox regression models to evaluate the interaction between predicted SCD/mortality risk and ICD use for mortality. Of 13 475 patients, only 15.5% had an ICD. Those with higher predicted proportional SCD risk (>45%) had an ∼80% higher likelihood to have an ICD. Other predictors of non-use were follow-up in primary versus specialty care, higher comorbidity burden and lower socioeconomic status. ICD use was associated with lower mortality only in patients with higher predicted SCD and lower mortality risk (34% and 37% relative risk reduction for 3-year all-cause and cardiovascular mortality, respectively). In this subgroup of patients, underuse of ICD was 81.8%.

conclusionIn a contemporary registry, only 15.5% of patients with an indication for primary prevention ICD received the device. While a high predicted proportional SCD risk was appropriately linked to ICD use, the lack of specialized follow-up, higher comorbidity burden, and lower socioeconomic status were major unjustified impediments to implementation. Our findings suggest areas for improving ICD use for primary prevention of SCD in clinical practice.

Indexed as

Defibrillators, ImplantableHeart FailureDeath, Sudden, CardiacHumansPrimary PreventionRisk FactorsStroke VolumeGuideline recommendationHeart failure with reduced ejection fractionImplantable cardioverter-defibrillatorImplementationPrimary preventionUnderuse

Identifiers

PMID35502681
PMCPMC9545916
OpenAlexW4225392865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.